Last-Hope drug offered to transplant patients with deadly blood clotting disorder
Disease control
APPROVED_FOR_MARKETING
This program provides access to the investigational drug narsoplimab for patients who develop a serious blood vessel complication called HSCT-TMA after a stem cell transplant. It's for adults and children who have undergone transplant and developed this life-threatening condition…
Sponsor: Omeros Corporation • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC